Advanced RCC: dalantercept shows promise in phase 2 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • Dalantercept plus axitinib (Inlyta) demonstrated a favorable safety profile and clinically meaningful antitumor activity in patients with previously treated renal cell carcinoma (RCC).
Why this matters
  • Dual angiogenic blockade is appealing considering the limited duration of activity of ...